Experiment 639674
Worktypes
Compounds isolated
Details
| Property | Value |
|---|---|
| Pharmacology | |
| Administration route | IV |
| Organism | Empty organism |
| Citation | TSUBOTA,A: KUMADA,H: ARASE,Y: CHAYAMA,K: SAITOH,S: IKEDA,K: KOBAYASHI,M: SUZUKI,Y: MURASHIMA,N:. (1999). COMBINED URSODEOXYCHOLIC ACID AND GLYCYRRHIZIN THERAPY FOR CHRONIC HEPATITIS C VIRUS INFECTION: A RANDOMIZED CONTROLLED TRIAL IN 170 PATIENTS.. 11(10) |
| Amount utilized | |
| Compound isolated | |
| Disease | A PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF GLYCYRRHIZIN (GROUP G) COMPARED WITH GLYCYRRHIZIN PLUS URSODEOXYCHOLIC ACID (G+U) IN 170 PATIENTS WAS TO ASSESS THE EFFICACY AND SAFETY OF THERPAY FOR CHRONIC HEPATITIS C VIRUS INFECTION. SERUM ASPARATE TRANSAMINASE AND ALANINE TRANSAMINASE CONCENTRATION SIGNIFICANTLY DECREASED DURING TREATMENT IN BOTH GROUPS, SERUM GAMMA-GLUTAMYL TRANSPEPTIDASE CONCENTRATIONS FELL SIGNIFICANTLY ONLY IN GROUP G+U. CONCENTRACTIONS OF ALL THREE ENZYMES FELL SIGNIFICANTLY MORE IN GROUP G+U THAN IN GROUP G, AND HAD NORMALIZED IN MORE CASES WHEN THE TRIAL ENDED AT 24 WEEKS. HOWEVER, LEVELS OF HCV VIRAEMIA DID NOT CHANGE DURING THE TRIAL IN EITHER GROUP. MULTIPLE REGRESSION ANALYSIS LINKED ONLY THE TREATMENT REGIMEN, NOT HCV-RELATED FACTORS OR LIVER HISTOLOGY, TO THE DEGREE OF SERUM ENZYME REDUCTION. NO ADVERSE EFFECTS WERE NOTED IN EITHER GROUP. THE COMBINED THERAPY WITH URODEOXYCHOLIC ACID AND GLYCYRRHIZIN IS SAFE AND EFFECTIVE IN IMPROVING LIVER-SPECIFIC ENZYME ABNORMALITIES, AND MAY BE AN ALTERNATIVE TO INTERFERON IN CHRONIC HEPATITIS C VIRUS INFECTION, ESPECIALLY FOR INTERFERON-RESISTANT OR UNSTABLE PATIENTS. |
| Dose amount | 100.0 MG |
| Number | 1 |
| Qualitative result | ACTIVE |
| Animal | HUMAN ADULT |
| Per unit | DAY |
| Dose expression | DOSE |
| Gender | GIVEN TO BOTH SEXES |